Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.1
5.0
Journals
Nutrients
Special Issues
Biological and Clinical Implication of Fatty Acids in Liver and...
nutrients-logo
Submit to Nutrients Review for Nutrients Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Biological and Clinical Implication of Fatty Acids in Liver and Cardiometabolic Disorders

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Nutrition and Public Health".

Deadline for manuscript submissions: closed (25 November 2024) | Viewed by 14401

Special Issue Editor

Dr. Alexander V. Sorokin

E-Mail Website
Guest Editor
Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892-1666, USA
Interests: atherosclerosis; lipoproteins; inflammation; cardiology; bioactive lipids; imaging; cardiovascular disease; prevention

Special Issue Information

Dear Colleagues,

Cardiometabolic disorders represent a significant public health concern, which puts millions of people worldwide at a higher risk of developing heart disease and type 2 diabetes with associated healthcare expenses. Among the established risk factors comprising cardiometabolic disorders, such as abdominal obesity, insulin resistance and hypertension, non-alcoholic fatty liver disease (NAFLD) has been of particular clinical interest. Moreover, accompanying dyslipidemia, elevated triglycerides and impaired resolution of inflammation compelled international experts to revise the current understanding of NAFLD and propose a new definition, that more accurately represents pathophysiological mechanisms behind NAFLD and cardiometabolic complications. Thus, metabolic dysfunction-associated fatty liver disease (MAFLD) term has been coined. Finally, with the recent progress in fatty acids research and clinical application of n–3 fatty acids, particularly icosapent ethyl (IPE) treatment, this Special Issue of Nutrients should be of great interest to the wide community of researchers and healthcare professionals from different fields of study.

Dr. Alexander V. Sorokin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fatty acids
  • inflammation
  • lipid mediators
  • lipoproteins
  • cardiometabolic disorders
  • liver disease
  • atherosclerosis
  • dyslipidemia
  • diet

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

48 pages, 1853 KiB  
Review
Emerging Roles for Sphingolipids in Cardiometabolic Disease: A Rational Therapeutic Target?
by Daniel Foran, Charalambos Antoniades and Ioannis Akoumianakis
Nutrients 2024, 16(19), 3296; https://doi.org/10.3390/nu16193296 - 28 Sep 2024
Cited by 4 | Viewed by 2533
Abstract
Cardiovascular disease is a leading cause of morbidity and mortality. New research elucidates increasingly complex relationships between cardiac and metabolic health, giving rise to new possible therapeutic targets. Sphingolipids are a heterogeneous class of bioactive lipids with critical roles in normal human physiology. [...] Read more.
Cardiovascular disease is a leading cause of morbidity and mortality. New research elucidates increasingly complex relationships between cardiac and metabolic health, giving rise to new possible therapeutic targets. Sphingolipids are a heterogeneous class of bioactive lipids with critical roles in normal human physiology. They have also been shown to play both protective and deleterious roles in the pathogenesis of cardiovascular disease. Ceramides are implicated in dysregulating insulin signalling, vascular endothelial function, inflammation, oxidative stress, and lipoprotein aggregation, thereby promoting atherosclerosis and vascular disease. Ceramides also advance myocardial disease by enhancing pathological cardiac remodelling and cardiomyocyte death. Glucosylceramides similarly contribute to insulin resistance and vascular inflammation, thus playing a role in atherogenesis and cardiometabolic dysfunction. Sphingosing-1-phosphate, on the other hand, may ameliorate some of the pathological functions of ceramide by protecting endothelial barrier integrity and promoting cell survival. Sphingosine-1-phosphate is, however, implicated in the development of cardiac fibrosis. This review will explore the roles of sphingolipids in vascular, cardiac, and metabolic pathologies and will evaluate the therapeutic potential in targeting sphingolipids with the aim of prevention and reversal of cardiovascular disease in order to improve long-term cardiovascular outcomes. Full article
(This article belongs to the Special Issue Biological and Clinical Implication of Fatty Acids in Liver and Cardiometabolic Disorders)
►▼ Show Figures

Figure 1

17 pages, 666 KiB  
Review
Different Dietary Approaches, Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A Literature Review
by Jose D. Torres-Peña, Antonio P. Arenas-de Larriva, Juan F. Alcala-Diaz, Jose Lopez-Miranda and Javier Delgado-Lista
Nutrients 2023, 15(6), 1483; https://doi.org/10.3390/nu15061483 - 20 Mar 2023
Cited by 24 | Viewed by 9628
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the first cause of chronic liver disease and is also associated with other harmful entities such as obesity, metabolic syndrome, dyslipidemia, and diabetes. NAFLD is a significant public health concern worldwide, impacting individuals of all ages, and [...] Read more.
Non-alcoholic fatty liver disease (NAFLD) is the first cause of chronic liver disease and is also associated with other harmful entities such as obesity, metabolic syndrome, dyslipidemia, and diabetes. NAFLD is a significant public health concern worldwide, impacting individuals of all ages, and its prevalence is projected to increase in the near future due to its connection with obesity. Intrinsic (genetics) and external (lifestyle) factors may also modulate NAFLD, and, in turn, may partly explain the observed relationship between NAFLD and cardiovascular disease (CVD). Although many drugs are been tested to treat NAFLD, to date, no drug has indication to specifically treat this disorder. Thus, the current management of NAFLD relies on lifestyle modifications and specifically on weight loss, physical activity, and the intake of a healthy diet. In the present narrative review, we will discuss the effects of certain dietary patterns on NAFLD incidence and progression. Full article
(This article belongs to the Special Issue Biological and Clinical Implication of Fatty Acids in Liver and Cardiometabolic Disorders)
►▼ Show Figures

Graphical abstract

Other

Jump to: Review

7 pages, 411 KiB  
Brief Report
Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment
by Masato Hamasaki, Naoki Sakane and Kazuhiko Kotani
Nutrients 2024, 16(21), 3686; https://doi.org/10.3390/nu16213686 - 29 Oct 2024
Viewed by 1381
Abstract
Background/Objectives: Fatty acids are involved in some hepatic disorders. The proprotein convertase subtilisin kexin 9 (PCSK9) inhibits the uptake of low-density lipoproteins (LDLs), which contain lipids, into the liver and may thus be associated with nonalcoholic fatty liver disease (NAFLD), a cardiovascular disorder [...] Read more.
Background/Objectives: Fatty acids are involved in some hepatic disorders. The proprotein convertase subtilisin kexin 9 (PCSK9) inhibits the uptake of low-density lipoproteins (LDLs), which contain lipids, into the liver and may thus be associated with nonalcoholic fatty liver disease (NAFLD), a cardiovascular disorder (CVD) risk. Statins reduce blood LDL–cholesterol (LDL-C) levels and CVD risk and can attenuate the development of NAFLD while increasing blood PCSK9 levels. Methods: We investigated the correlation between PCSK9 and liver conditions in patients with familial hypercholesterolemia (FH), a CVD risk population with elevated blood LDL-C levels, under statin treatment. Blood tests for lipids, PCSK9, and liver function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) were performed in patients with FH taking statins (n = 25, mean age = 57 years, 12% of males). The ALT:AST ratio was used as a marker of NAFLD risk. Results: The mean LDL-C level was 3.38 mmol/L, and the median PCSK9 level was 312 ng/mL. The median ALT:AST ratio was 0.88. A significant negative correlation was observed between the PCSK9 and ALT:AST ratio (β = −0.67, p < 0.05). Conclusions: Their negative correlation might give a hypothetical insight into the effect of statin treatment on the development of NAFLD, in relation to PCSK9 behavior, in patients with FH. Full article
(This article belongs to the Special Issue Biological and Clinical Implication of Fatty Acids in Liver and Cardiometabolic Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop